Patrick R. Trucchio
Stock Analyst at HC Wainwright & Co.
(4.19)
# 390
Out of 5,148 analysts
60
Total ratings
56.14%
Success rate
14.77%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Patrick R. Trucchio
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HELP Cybin | Maintains: Buy | $55 → $95 | $7.45 | +1,175.17% | 1 | Mar 2, 2026 | |
| DFTX Definium Therapeutics | Maintains: Buy | $55 → $70 | $17.51 | +299.77% | 1 | Mar 2, 2026 | |
| GHRS GH Research | Maintains: Buy | $35 → $70 | $15.28 | +358.27% | 2 | Mar 2, 2026 | |
| ATAI AtaiBeckley | Maintains: Buy | $15 → $25 | $3.69 | +578.43% | 2 | Mar 2, 2026 | |
| CMPS COMPASS Pathways | Maintains: Buy | $40 → $70 | $6.89 | +915.97% | 1 | Mar 2, 2026 | |
| HRMY Harmony Biosciences Holdings | Reiterates: Buy | $55 | $28.55 | +92.64% | 3 | Feb 25, 2026 | |
| ALNY Alnylam Pharmaceuticals | Reiterates: Buy | $510 | $319.36 | +59.69% | 4 | Feb 18, 2026 | |
| ARWR Arrowhead Pharmaceuticals | Reiterates: Buy | $100 | $66.13 | +51.22% | 5 | Feb 10, 2026 | |
| QURE uniQure | Reiterates: Buy | $70 | $8.98 | +679.51% | 6 | Feb 10, 2026 | |
| SGMO Sangamo Therapeutics | Reiterates: Buy | $10 | $0.41 | +2,369.14% | 2 | Feb 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $100 | $32.12 | +211.33% | 2 | Feb 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $0.46 | +2,063.57% | 1 | Jan 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $115 | $80.17 | +43.45% | 3 | Dec 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $15 | $8.96 | +67.41% | 2 | Dec 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $28.15 | +77.62% | 2 | Dec 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $1.82 | +2,097.80% | 4 | Dec 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.40 | +614.29% | 1 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $60 | $26.99 | +122.30% | 3 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $10 | $1.00 | +902.51% | 1 | Nov 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $25 | $3.89 | +542.67% | 2 | Nov 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $10 | $1.67 | +500.60% | 3 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $50 | $19.72 | +153.55% | 2 | Oct 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $4.18 | +187.08% | 2 | Oct 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $80 | $27.82 | +187.56% | 2 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $75 | $5.63 | +1,233.33% | 1 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $6.82 | +633.30% | 2 | Sep 12, 2025 |
Cybin
Mar 2, 2026
Maintains: Buy
Price Target: $55 → $95
Current: $7.45
Upside: +1,175.17%
Definium Therapeutics
Mar 2, 2026
Maintains: Buy
Price Target: $55 → $70
Current: $17.51
Upside: +299.77%
GH Research
Mar 2, 2026
Maintains: Buy
Price Target: $35 → $70
Current: $15.28
Upside: +358.27%
AtaiBeckley
Mar 2, 2026
Maintains: Buy
Price Target: $15 → $25
Current: $3.69
Upside: +578.43%
COMPASS Pathways
Mar 2, 2026
Maintains: Buy
Price Target: $40 → $70
Current: $6.89
Upside: +915.97%
Harmony Biosciences Holdings
Feb 25, 2026
Reiterates: Buy
Price Target: $55
Current: $28.55
Upside: +92.64%
Alnylam Pharmaceuticals
Feb 18, 2026
Reiterates: Buy
Price Target: $510
Current: $319.36
Upside: +59.69%
Arrowhead Pharmaceuticals
Feb 10, 2026
Reiterates: Buy
Price Target: $100
Current: $66.13
Upside: +51.22%
uniQure
Feb 10, 2026
Reiterates: Buy
Price Target: $70
Current: $8.98
Upside: +679.51%
Sangamo Therapeutics
Feb 10, 2026
Reiterates: Buy
Price Target: $10
Current: $0.41
Upside: +2,369.14%
Feb 4, 2026
Reiterates: Buy
Price Target: $100
Current: $32.12
Upside: +211.33%
Jan 22, 2026
Reiterates: Buy
Price Target: $10
Current: $0.46
Upside: +2,063.57%
Dec 30, 2025
Reiterates: Buy
Price Target: $115
Current: $80.17
Upside: +43.45%
Dec 30, 2025
Reiterates: Buy
Price Target: $15
Current: $8.96
Upside: +67.41%
Dec 22, 2025
Reiterates: Buy
Price Target: $50
Current: $28.15
Upside: +77.62%
Dec 16, 2025
Reiterates: Buy
Price Target: $40
Current: $1.82
Upside: +2,097.80%
Dec 8, 2025
Initiates: Buy
Price Target: $10
Current: $1.40
Upside: +614.29%
Dec 3, 2025
Reiterates: Buy
Price Target: $60
Current: $26.99
Upside: +122.30%
Nov 17, 2025
Maintains: Buy
Price Target: $5 → $10
Current: $1.00
Upside: +902.51%
Nov 12, 2025
Maintains: Buy
Price Target: $30 → $25
Current: $3.89
Upside: +542.67%
Nov 3, 2025
Maintains: Buy
Price Target: $5 → $10
Current: $1.67
Upside: +500.60%
Oct 24, 2025
Maintains: Buy
Price Target: $10 → $50
Current: $19.72
Upside: +153.55%
Oct 20, 2025
Reiterates: Buy
Price Target: $12
Current: $4.18
Upside: +187.08%
Oct 10, 2025
Reiterates: Buy
Price Target: $80
Current: $27.82
Upside: +187.56%
Sep 16, 2025
Reiterates: Buy
Price Target: $75
Current: $5.63
Upside: +1,233.33%
Sep 12, 2025
Reiterates: Buy
Price Target: $50
Current: $6.82
Upside: +633.30%